293 related articles for article (PubMed ID: 29217757)
1. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
[TBL] [Abstract][Full Text] [Related]
2. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
[TBL] [Abstract][Full Text] [Related]
3. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
4. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.
Pierce JD; Mahoney DE; Hiebert JB; Thimmesch AR; Diaz FJ; Smith C; Shen Q; Mudaranthakam DP; Clancy RL
BMC Cardiovasc Disord; 2018 Apr; 18(1):57. PubMed ID: 29606104
[TBL] [Abstract][Full Text] [Related]
5. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.
Butler J; Khan MS; Anker SD; Fonarow GC; Kim RJ; Nodari S; O'Connor CM; Pieske B; Pieske-Kraigher E; Sabbah HN; Senni M; Voors AA; Udelson JE; Carr J; Gheorghiade M; Filippatos G
J Card Fail; 2020 May; 26(5):429-437. PubMed ID: 32068002
[TBL] [Abstract][Full Text] [Related]
6. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
[TBL] [Abstract][Full Text] [Related]
7. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.
Saad A; Herrmann SMS; Eirin A; Ferguson CM; Glockner JF; Bjarnason H; McKusick MA; Misra S; Lerman LO; Textor SC
Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28916603
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
[TBL] [Abstract][Full Text] [Related]
9. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
[TBL] [Abstract][Full Text] [Related]
10. First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure.
Ward CL; Jamieson V; Nabata T; Sharpe J; Dozono K; Suto F; Hashimoto Y; Gussak I
Clin Ther; 2016 May; 38(5):1109-21. PubMed ID: 27001444
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.
Berg-Hansen K; Gopalasingam N; Christensen KH; Ladefoged B; Andersen MJ; Poulsen SH; Borlaug BA; Nielsen R; Møller N; Wiggers H
Circulation; 2024 May; 149(19):1474-1489. PubMed ID: 38533643
[TBL] [Abstract][Full Text] [Related]
12. Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction.
Nanayakkara S; Byrne M; Mak V; Carter K; Dean E; Kaye DM
J Am Heart Assoc; 2020 Jul; 9(13):e015026. PubMed ID: 32552264
[TBL] [Abstract][Full Text] [Related]
13. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).
Wan SH; Stevens SR; Borlaug BA; Anstrom KJ; Deswal A; Felker GM; Givertz MM; Bart BA; Tang WH; Redfield MM; Chen HH
Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27512103
[TBL] [Abstract][Full Text] [Related]
14. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).
St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B
J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005
[TBL] [Abstract][Full Text] [Related]
15. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
McMurray JJV; Ponikowski P; Bolli GB; Lukashevich V; Kozlovski P; Kothny W; Lewsey JD; Krum H;
JACC Heart Fail; 2018 Jan; 6(1):8-17. PubMed ID: 29032139
[TBL] [Abstract][Full Text] [Related]
16. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
[TBL] [Abstract][Full Text] [Related]
17. Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro.
Robbins N; Gilbert M; Kumar M; McNamara JW; Daly P; Koch SE; Conway G; Effat M; Woo JG; Sadayappan S; Rubinstein J
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29331959
[TBL] [Abstract][Full Text] [Related]
18. Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
Zamani P; Akers S; Soto-Calderon H; Beraun M; Koppula MR; Varakantam S; Rawat D; Shiva-Kumar P; Haines PG; Chittams J; Townsend RR; Witschey WR; Segers P; Chirinos JA
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28219917
[TBL] [Abstract][Full Text] [Related]
19. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
Florea VG; Rector TS; Anand IS; Cohn JN
Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
[TBL] [Abstract][Full Text] [Related]
20. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group.
Mills RM; LeJemtel TH; Horton DP; Liang C; Lang R; Silver MA; Lui C; Chatterjee K
J Am Coll Cardiol; 1999 Jul; 34(1):155-62. PubMed ID: 10400005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
